BACKGROUND: Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy. METHODS: Retrospective analysis of a prospective database identified patients with MML who underwent liver resection from 1980 to 2008. RESULTS: A total of 539 patients had MML, and 39% (204 of 539) had tumor collected for TIL. A total of 17% (35 of 204) underwent liver resection for TIL. The 3-year overall survival was 53%. Lack of extrahepatic disease (P = .026), negative margin (P = .056), and single hepatic metastasis (P = .04) predicted survival after univariate analysis. Only lack of extrahepatic disease remained a significant predictor of survival after multivariate analysis (P = .043). A total of 31% (11 of 35) underwent complete resection without TIL, and 69% (24 of 35) underwent resection with synchronous intrahepatic and extrahepatic disease with intent to receive TIL. For 9 of 11 patients (2 of 11 excluded for gene therapy), 3-year survival was 80%. A total of 4 (44%) of 9 experienced recurrence, with a median disease-free survival of 1.2 years. For 24 patients (69%) with residual disease, 3-year survival was 51% (2 of 24 excluded for gene therapy). A total of 63% (15 of 24) received postoperative TIL (3-year survival 65%), and 29% (7 of 24) did not. A total of 40% (6 of 15) had disease that partially responded to TIL; the disease of 67% (4 of 6) had not progressed at median follow-up of 55 months (range, 42-197+ months). The seven patients who did not receive TIL had a median survival of 4.6 months. CONCLUSIONS: Resection of MML with TIL should be considered because it can result in prolonged survival in a highly selected group of patients.
BACKGROUND:Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy. METHODS: Retrospective analysis of a prospective database identified patients with MML who underwent liver resection from 1980 to 2008. RESULTS: A total of 539 patients had MML, and 39% (204 of 539) had tumor collected for TIL. A total of 17% (35 of 204) underwent liver resection for TIL. The 3-year overall survival was 53%. Lack of extrahepatic disease (P = .026), negative margin (P = .056), and single hepatic metastasis (P = .04) predicted survival after univariate analysis. Only lack of extrahepatic disease remained a significant predictor of survival after multivariate analysis (P = .043). A total of 31% (11 of 35) underwent complete resection without TIL, and 69% (24 of 35) underwent resection with synchronous intrahepatic and extrahepatic disease with intent to receive TIL. For 9 of 11 patients (2 of 11 excluded for gene therapy), 3-year survival was 80%. A total of 4 (44%) of 9 experienced recurrence, with a median disease-free survival of 1.2 years. For 24 patients (69%) with residual disease, 3-year survival was 51% (2 of 24 excluded for gene therapy). A total of 63% (15 of 24) received postoperative TIL (3-year survival 65%), and 29% (7 of 24) did not. A total of 40% (6 of 15) had disease that partially responded to TIL; the disease of 67% (4 of 6) had not progressed at median follow-up of 55 months (range, 42-197+ months). The seven patients who did not receive TIL had a median survival of 4.6 months. CONCLUSIONS: Resection of MML with TIL should be considered because it can result in prolonged survival in a highly selected group of patients.
Authors: P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Srinevas K Reddy; Andrew S Barbas; Carlos E Marroquin; Michael A Morse; Paul C Kuo; Bryan M Clary Journal: J Am Coll Surg Date: 2007-03 Impact factor: 6.113
Authors: Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley Journal: Nat Rev Cancer Date: 2008-04 Impact factor: 60.716
Authors: Douglas B Zippel; Michal Besser; Roni Shapira; Alon Ben-Nun; David Goitein; Tima Davidson; Abraham J Treves; Gal Markel; Jacob Schachter; Moshe Z Papa Journal: Exp Ther Med Date: 2012-02-28 Impact factor: 2.447
Authors: Melissa M Alvarez-Downing; Suzanne M Inchauste; Mark E Dudley; Donald E White; John R Wunderlich; Steven A Rosenberg; Udai S Kammula Journal: World J Surg Oncol Date: 2012-06-22 Impact factor: 2.754
Authors: John E Mullinax; Michael E Egger; Martin McCarter; Bradley J Monk; Eric M Toloza; Susan Brousseau; Madan Jagasia; Amod Sarnaik Journal: Cancer J Date: 2022 Jul-Aug 01 Impact factor: 2.074
Authors: Richard D Carvajal; Gary K Schwartz; Tongalp Tezel; Brian Marr; Jasmine H Francis; Paul D Nathan Journal: Br J Ophthalmol Date: 2016-08-29 Impact factor: 4.638